Kymera Therapeutics, Inc. - COMMON STOCK (KYMR)

Historical Holders from Q3 2020 to Q4 2025

Type / Class
Equity / COMMON STOCK
Symbol
KYMR on Nasdaq
Shares outstanding
79,719,412
Price per share
$77.82
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares as of 30 Sep 2025
80,867,584
Total reported value
$4,576,968,145
% of total 13F portfolios
0%
Share change
+1,990,132
Value change
+$137,544,818
Avg buy value change
+0%
Avg sell value change
-0%
Number of holders
206
Price from insider filings
$32.07
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Kymera Therapeutics, Inc. - COMMON STOCK (KYMR) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
FMR LLC 11% +38% $694,720,745 +$237,235,847 8,928,574 +52% FMR LLC 31 Dec 2025
BAKER BROS. ADVISORS LP 11% +14% $569,111,115 +$131,852,757 8,676,797 +30% Baker Bros. Advisors LP 09 Dec 2025
BIOTECHNOLOGY VALUE FUND L P 8.5% $450,459,592 6,867,809 BVF PARTNERS L P/IL 11 Dec 2025
WELLINGTON MANAGEMENT GROUP LLP 7.7% -17% $234,436,742 -$27,266,796 5,372,061 -10% Wellington Management Group LLP 30 Jun 2025
VANGUARD GROUP INC 8% $117,183,181 5,231,392 The Vanguard Group 31 Mar 2025
PRICE T ROWE ASSOCIATES INC /MD/ 7.1% $288,530,046 5,097,704 T. Rowe Price Associates, Inc. 30 Sep 2025
BlackRock, Inc. 5.4% $122,349,813 3,803,227 BlackRock, Inc. 30 Jun 2025
As of 30 Sep 2025, Kymera Therapeutics, Inc. - COMMON STOCK (KYMR) has 206 institutional shareholders filing 13F forms. They hold 80,867,584 shares. .

Top 25 institutional shareholders own 83% of the company.

Filer Ownership Nb Shares Share Change % Portfolio % Holdings Value
BAKER BROS. ADVISORS LP 8.3% 6,651,429 0% 2.7% $376,470,881
Avoro Capital Advisors LLC 8% 6,350,000 -3.1% 4.6% $359,410,000
FMR LLC 7.4% 5,879,611 +8.2% 0.02% $332,785,989
BVF INC/IL 6.9% 5,502,710 0% 13% $311,453,386
VANGUARD GROUP INC 6.8% 5,421,722 -3.5% 0% $306,869,465
WELLINGTON MANAGEMENT GROUP LLP 6.5% 5,195,691 -3.3% 0.05% $294,076,110
PRICE T ROWE ASSOCIATES INC /MD/ 6.4% 5,097,378 -26% 0.03% $288,513,000
Atlas Venture Life Science Advisors, LLC 6.1% 4,896,462 0% 37% $277,139,749
BlackRock, Inc. 5.5% 4,365,448 +5.2% 0% $247,084,359
Siren, L.L.C. 4.3% 3,428,150 0% 7.6% $194,033,290
STATE STREET CORP 2.5% 2,019,454 +30% 0% $114,301,096
GEODE CAPITAL MANAGEMENT, LLC 1.6% 1,276,766 +7% 0% $72,276,364
Capital Research Global Investors 1.6% 1,262,182 0% 0.01% $71,439,501
JENNISON ASSOCIATES LLC 1.3% 1,027,739 +25% 0.03% $58,170,027
Driehaus Capital Management LLC 1.2% 939,094 +0.56% 0.38% $53,152,720
UBS AM, A DISTINCT BUSINESS UNIT OF UBS ASSET MANAGEMENT AMERICAS LLC 1.1% 863,762 +5.5% 0.01% $48,888,930
Holocene Advisors, LP 1.1% 840,333 0.11% $47,562,848
Merck & Co., Inc. 0.97% 772,165 0% 19% $43,704,539
Commodore Capital LP 0.94% 750,000 0% 2.1% $42,450,000
DIMENSIONAL FUND ADVISORS LP 0.92% 731,420 +30% 0.01% $41,409,153
GOLDMAN SACHS GROUP INC 0.89% 711,444 +155% 0.01% $40,267,730
UBS Group AG 0.81% 648,718 +16% 0.01% $36,717,439
EVENTIDE ASSET MANAGEMENT, LLC 0.81% 644,590 +14% 0.6% $36,483,859
Alyeska Investment Group, L.P. 0.77% 615,091 +1130% 0.11% $34,814,151
T. Rowe Price Investment Management, Inc. 0.77% 611,221 +574% 0.02% $34,596,000

Institutional Holders of Kymera Therapeutics, Inc. - COMMON STOCK (KYMR) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (% of par) Investors
2025 Q4 22,991 $1,789,187 +$1,119,693 7,781.51% 2
2025 Q3 80,867,584 $4,576,968,145 +$137,544,818 5,660% 206
2025 Q2 78,801,090 $3,438,767,375 +$270,834,411 4,364% 209
2025 Q1 72,808,716 $1,995,262,892 +$5,348,220 2,737% 171
2024 Q4 71,734,044 $2,885,597,297 +$18,569,333 4,023% 177
2024 Q3 68,960,007 $3,264,074,987 -$2,272,100 4,733% 173
2024 Q2 67,394,647 $2,011,764,703 +$10,124,429 2,985% 153
2024 Q1 67,081,234 $2,696,673,715 +$295,861,006 4,020% 159
2023 Q4 224,963 $5,764,278 +$3,181,685 2,546.01% 4
2023 Q3 57,205,249 $795,164,056 -$17,579,562 1,390% 118
2023 Q2 58,035,560 $1,334,220,622 +$24,134,659 2,299% 121
2023 Q1 56,830,949 $1,682,653,801 +$23,240,441 2,963% 121
2022 Q4 56,095,964 $1,400,212,729 +$97,828,650 2,496% 114
2022 Q3 51,020,711 $1,110,776,844 +$28,026,304 2,177% 114
2022 Q2 49,240,285 $969,113,847 +$11,517,000 1,968.99% 97
2022 Q1 45,260,761 $1,915,201,786 +$61,683,351 4,232% 124
2021 Q4 43,134,018 $2,737,370,438 +$117,402,785 6,349% 122
2021 Q3 34,293,472 $2,014,883,491 +$486,024,539 5,874% 113
2021 Q2 26,536,322 $1,287,767,574 +$190,156,234 4,850% 109
2021 Q1 22,820,749 $886,801,865 +$90,209,096 3,886% 94
2020 Q4 20,039,060 $1,230,826,136 +$52,330,949 6,200% 72
2020 Q3 16,362,026 $527,472,000 +$527,472,105 3,231% 50